The team at Goldman Sachs has been running the rule over the healthcare sector following the conclusion of earnings season.
Two ASX 200 healthcare shares that have been given the thumbs up by the broker are listed below. Hereâs what its analysts are saying about them:
Cochlear Limited (ASX: COH)
This hearing solutions company could be a top option in the sector according to Goldman Sachs. Its analysts believe Cochlear is well-placed to outperform its guidance in FY 2023 thanks to improving trading conditions.
Goldman has a buy rating and $265.00 price target on its shares. It commented:
We believe Cochlear screens well on these fundamental factors, and largely avoids the margin uncertainties prevalent across other verticals. We expect a sequential improvement in momentum through 2H23 (further elective volume improvement and new processor launch momentum, potentially tempered by some moderation in Acoustics). We forecast above guidance in FY23E (GSe: $306m vs. $290-305m) and believe shares will now be further supported by a newly announced multi-year buyback program (GSe: $75m/year).
ResMed Inc. (ASX: RMD)
Another ASX 200 healthcare share that Goldman Sachs is bullish on is ResMed. It is forecasting double-digit earnings growth through to at least 2026. It also sees scope for even quicker growth depending on the Philips re-entry after a major product recall.
Goldman has a buy rating and $38.00 price target on this sleep treatment companyâs shares. It said:
The timing/nature of Philipsâ re-entry remains an important debate, but under most scenarios we expect excess demand through end-2023 at least. Whilst supply shortages and cost inflation mitigated the tailwinds through FY22, the benefits to RMD are significant, and could accrue over many years. As operational pressures continue to ease we see margin/cost dynamics improving, both near- and long-term. We expect a sequentially stronger 2H23, and currently model an EPS CAGR of +11% FY23-26E (with potential upside depending on how competitive dynamics develop).
The post Buy these excellent ASX 200 healthcare shares: Goldman Sachs appeared first on The Motley Fool Australia.
FREE Beginners Investing Guide
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of March 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Brokers name 2 blue chip ASX 100 shares to buy
- How Iâd invest $20,000 in ASX 200 shares to aim for a million
- 3 incredible ASX 200 growth shares to buy: analysts
- $20k invested in these ASX shares 10 years ago is now worth over $100k
- Buy these ASX 200 growth shares: Goldman Sachs
from The Motley Fool Australia https://ift.tt/oxSdW03
Stock Pick 